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Bulgarian Academy of Sciences, Sofia, BulgariaABSTRACT We consider the size distribution of amyloid nanofibrils (protofilaments) in nucleating protein solutions when the
nucleation process occurs by the mechanism of direct polymerization of b-strands (extended peptides or protein segments) into
b-sheets. Employing the atomistic nucleation theory, we derive a general expression for the stationary size distribution of
amyloid nanofibrils constituted of successively layered b-sheets. The application of this expression to amyloid b1-40 (Ab40) fibrils
allows us to determine the nanofibril size distribution as a function of the protein concentration and temperature. The distribution
is most remarkable with its exhibiting a series of peaks positioned at ‘‘magic’’ nanofibril sizes (or lengths), which are due to deep
local minima in the work for fibril formation. This finding of magic sizes or lengths is consistent with experimental results for the
size distribution of aggregates in solutions of Ab40 proteins. Also, our approach makes it possible to gain insight into the effect of
point mutations on the nanofibril size distribution, an effect that may play a role in experimentally observed substantial differ-
ences in the fibrillation lag-time of wild-type and point-mutated amyloid-b proteins.INTRODUCTIONThe assembly of proteins into amyloid fibrils is an important
phenomenon with wide implications ranging from human
disease to nanoscience. Amyloid fibril formation is associ-
ated with a growing number of neurological and systemic
diseases (1) including Alzheimer’s and Parkinson’s dis-
eases, and the application of amyloid fibrils as molecular
building blocks in biosensors, tissue engineering, and anti-
bacterial agents has been demonstrated (2). The main
insight into the structures formed by proteins comes from
structural biology experiments. Such experiments are very
challenging for protein aggregates because of the aggregate
transient nature and structural heterogeneity (1). An essen-
tial point in our current understanding is that peptides and
proteins unrelated in sequence and structure have been
shown to convert into large fibrillar aggregates including
amyloid fibrils (1). These aggregates share a common
cross-b structure formed by intertwined layers of b-sheets
extending in a direction parallel to the fibril elongation
axis (3–8). Oligomeric aggregates are often found as precur-
sors of amyloid fibrils (9–11) and their structure can vary
from that of highly disordered aggregates that are composed
of unstructured proteins to that of nativelike aggregates in
which the proteins retain their native state.
It is now well established (9,10,12–30) that fibrillar
protein aggregates can form by a nucleation mechanism.
Time-resolved optical experiments that measure the fluores-
cence signal arising from a dye-binding molecule such as
thioflavin-T bound to the protein aggregate have been
used to determine the lag time, during which no aggregates
are detected, and the maximal rate of conversion of proteinSubmitted September 13, 2011, and accepted for publication September 30,
2011.
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0006-3495/11/11/2232/10 $2.00monomers into aggregates. Experiments (28,31–41) have
been performed to reveal the relationship between the phys-
icochemical properties of the natural amino acids and the
kinetics of amyloid formation. These experiments have in
turn been used to substantiate phenomenological models
(42–46) able to predict changes in the propensity of proteins
to aggregate upon mutation as well as to identify amino-acid
sequences of proteins that are likely to belong to the fibril
core. To gain more insight into the nucleation mechanism
and to determine important nucleation parameters such as
the fibril nucleus size and nucleation rate, it is necessary
to monitor the time evolution of the aggregates formed in
a nucleating protein solution. Recently, small-angle x-ray
scattering (47,48) and fluorescence correlation spectroscopy
experiments (29,49) have been used to monitor the popula-
tion, structural changes, and size of protein aggregates in the
solution. Understanding and interpreting such experiments
requires developing a theoretical framework describing
amyloid fibril nucleation.
In previous studies, we used concepts from the theory of
overall crystallization to describe the kinetics of overall
protein aggregation (50), and applied the classical and atom-
istic nucleation theories (CNT and ANT, respectively) to
treat the nucleation of amyloid fibrils when the process takes
place by the mechanism of direct polymerization of single
b-strands (extended peptides or protein segments) into
b-sheets (51,52). In this, our treatment differed from that
of Schmit et al. (53), who considered the case of amyloid
fibril nucleation in two steps: single b-strands assemble
into disordered oligomers, which then transform into
b-sheets. The application of ANT has been demonstrated
by correlating theoretical fibril nucleation rates with ex-
perimental lag times in the fibrillation kinetics of b2-micro-
globulin and amyloid b1-40 (Ab40) proteins (54). The
objective of this study is to employ nucleation theory fordoi: 10.1016/j.bpj.2011.09.053
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(protofilaments) in protein solutions when fibril nucleation
occurs in one step by polymerization of b-strands from
the solution directly into b-sheets. We derive a general
expression for the stationary size distribution of amyloid
nanofibrils constituted of successively layered b-sheets
and illustrate how this expression can be applied to the
smallest Ab40 protofilaments. The results obtained are
applicable to homogeneous nucleation that takes place
when the protein solution is sufficiently pure and/or strongly
supersaturated.THEORY
Modeling the amyloid nanofibril
Nucleation of nanosized amyloid fibrils by direct polymer-
ization of b-strands into b-sheets is operative when no fibril
precursors such as dropletlike oligomers are formed as a first
step in the fibril nucleation process. Fig. 1 defines the nano-
fibril and illustrates our model (52,54). The model is based
on reported structural and morphological results for amyloid
fibrils and microcrystals (3–8). Due to their strong hydrogen
bonds, the virtually fully extended protein b-strands can
arrange themselves into b-sheets that stretch forth along
the fibril lengthening axis (the m axis in Fig. 1). The
much weaker hydrophobicity-mediated interstrand bonds
cause the b-strands to assemble along the fibril thickening
axis (the i axis in Fig. 1) in such a way that a nanosized
amyloid fibril composed of successively layered b-sheets
can form. Because the fibril width is fixed and equal to
the b-strand length, the fibril can be considered as a two-
dimensional aggregate in the m,i plane, with building blocks
(the b-strands) arranged in a two-dimensional lattice with
simple rectangular symmetry (Fig. 1). Inasmuch as these
blocks play the role of the atoms in the original ANT,
with the term ‘‘atomistic’’ referring to the b-strands, this
theory is readily applicable to our nanofibril model.FIGURE 1 Schematic of nanosized fibril with thickness of two differ-
ently long b-sheets. The first and the second b-sheets are with length of
14 and 7 b-strands, respectively. Each of the 21 b-strands of the fibril is
composed of 19 amino acids. The 19 red and 19 blue lines shown for the
rightmost b-strand of the second b-sheet visualize the amino-acid strong
and weak broken bonds that are in direction of the fibril lengthening and
thickening (m and i) axes, respectively.Sequence-specific binding energies
In the atomistic approach to nucleation of amyloid fibrils
(52,54,55), important parameters are the binding energies
of the b-strands within the fibril. We denote by E (J) and
Eh (J) the binding energies between two nearest-neighbor
b-strands along the m and i axes in Fig. 1, respectively.
The excess energy of any n-sized nanofibril equals the fibril
total surface energy (51) that, according to ANT (52,55), is
given by the total energy lnE/2 þ lh,nEh/2 of the nearest-
neighbor broken-bonds at the periphery of the fibril cross
section in the m,i plane. In the above sum, n is the number
of b-strands in the fibril, and ln or lh,n is the number of all
nearest-neighbor broken bonds that are parallel to the fibril
m axis or i axis, respectively.
To calculate E and Eh, we assume that each amino acid
in a b-strand (19 such amino acids are illustrated in Fig. 1
by the prisms in the rightmost b-strand of the shorter
b-sheet) forms hydrogen bonds solely along the m axis,
and that hydrophobicity-mediated bonds can be formed
along both the m and i axes. Assuming further that bonds
can only be formed between nearest-neighbor amino acids,
the interstrand binding energies E and Eh are obtained by
summation of the bond energies of such amino acids over
all amino-acid pairs in neighboring b-strands:
E ¼
X
p

εjqð pÞ þ εh;jqð pÞ

; (1)
Eh ¼
X
εh; jqð phÞ: (2)
ph
In Eq. 1, the summation goes over all amino-acid pairs p in
two nearest-neighbor b-strands of a b-sheet, and in Eq. 2 it
goes over all amino-acid pairs ph in two nearest-neighbor
b-strands of two successive b-sheets. The energies of a near-
est-neighbor hydrogen amino-acid bond and a nearest-
neighbor, hydrophobicity-mediated amino-acid bond
between amino acids j and q are denoted by εjq (J) and
εh, jq (J), respectively (εjq >> εh, jq, because the hydrogen
bond is much stronger than the hydrophobicity-mediated
one).
The assignment of amino-acid, sequence-specific values
to the binding energies εjq and εh, jq allows application of
our nanofibril model to concrete protein systems. In this
study, the sequence-specific hydrogen-bond energies used
are based on a statistical analysis (45) of the frequency
that two residue types are found paired in neighboring
b-strands within b-sheets in globular proteins. The pairing
energy depends on the orientation (parallel or antiparallel)
of the b-strands. We denote by εPjq and ε
A
jq the dimension-
less pairing energies for the parallel and antiparallel orienta-
tion, respectively, and employ the εPjq and ε
A
jq values from
Table 1 of Trovato et al. (45) to modulate the basic unit ε (J)
of the hydrogen bond energy in such a way that the values of
the binding energy εjq lie in the interval [0, 2ε]:Biophysical Journal 101(9) 2232–2241
2234 Cabriolu et al.εjq ¼
2

ε APRO;ASP  εPðAÞjq


ε APRO;ASP  ε ACYS;CYS
ε: (3)
Here εACYS,CYS ¼ 2.57 and εAPRO,ASP ¼ 3.55 are, re-
spectively, the dimensionless energies of a CYS-CYS
pair and a PRO-ASP pair in an antiparallel b-sheet, and
εPðAÞjq equals ε
P
jq or ε
A
jq for the parallel or antiparallel orien-
tation. For the basic unit of the hydrogen bond we use
ε ¼ 6.95  1021 J (1 kcal/mol), a value in the range of
the hydrogen-bond energies measured experimentally (56).FIGURE 2 Sequence of nanofibril shapes corresponding to minimum
total surface energy, which depicts the fibril evolution when the transition
from one-dimensional to two-dimensional aggregate is at size nt ¼
E/Eh ¼ 14. The first three nanofibrils of size n0 j (pink) and n00j (blue) are
shown. (Hatched) First three fibril nuclei. (Pluses) Kink sites at which
b-strand attachment occurs at no surface-energy cost.Nanofibril evolution mechanism
The determination of the nanofibril size distribution requires
specification of the sequence of shapes that the fibril takes
during its evolution from the monomer size n ¼ 1 to the
considered size n > 1. In reality, there are many such
sequences, but we choose a sequence of shapes that have
the fibril equilibrium shape as a reference low-energy shape,
because the latter corresponds to the minimal fibril total
surface energy (51).
In this shape sequence (Fig. 2), the fibril initially evolves
as a single b-sheet and its transition from one-dimensional
to two-dimensional aggregate occurs at transition size nt
that is assumed to be given by the CNT formula (51) nt ¼
E/Eh. This size is an important parameter, because it charac-
terizes the fibril equilibrium shape, i.e., the fibril thermody-
namically favored aspect (length/thickness) ratio. Thus, the
(nt þ 1)-sized fibril (the one with n ¼ 15 in Fig. 2) has the
shape of 1b-sheet of length nt with one protein monomer
(b-strand) adsorbed on the sheet surface. This monomer
gives birth of the fibril second b-sheet and creates two
kink sites at the fibril surface (marked by plus signs in
Fig. 2). As shown in Cabriolu et al. (52), in a certain super-
saturation range the (nt þ 1)-sized fibril requires maximum
work for its formation and is therefore the so-called nucleus.
Further monomer attachment to a kink site does not increase
the fibril total surface energy, because the fibrils of size n ¼
nt þ 1, nt þ 2,., 2nt have the same total number of broken
bonds (see the fibrils with n ¼ 15, 16, and 28 in Fig. 2).
Because from n¼ 2nt to n¼ 2 2nt the CNTequilibrium
shape requires fibril thickness between one and two
b-sheets, the attachment of the next protein monomer to
the 2nt-sized fibril can be assumed to occur at one of the
two fibril ends. This lengthwise monomer attachment
creates a kink site at the end of the fibril of size n ¼
2nt þ 1 (the fibril with n ¼ 29 in Fig. 2) and the next mono-
mer is attached to this site with no surface-energy cost.
Thus, further fibril growth occurs by alternating creation
and annihilation of kink sites at the fibril ends until the fibril
reaches the size n ¼ 2  2nt (see the fibril with n ¼ 56 in
Fig. 2). At this size, the attachment of the next protein
monomer can be assumed to occur again to the surface ofBiophysical Journal 101(9) 2232–2241one of the fibril two b-sheets, because the CNT equilibrium
shape requires fibril thickness between two and three
b-sheets for fibril sizes from n¼ 2 2ntþ 1 to n¼ 3 3nt.
The fibril of size 2  2nt þ 1 (the one with n ¼ 57 in
Fig. 2) will therefore have the shape of a double b-sheet,
i.e., a 2b-sheet, of length 2nt with one protein monomer
adsorbed on the 2b-sheet surface rather than attached to
one of the 2b-sheet ends. The (2  2nt þ 1)-sized fibril is
also remarkable, because it is the nucleus in a corresponding
supersaturation range (52). The first monomer on the
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because it generates two kink sites at which subsequent
monomers can attach themselves without changing the total
number of the fibril broken bonds. In Fig. 2, the fibrils with
n ¼ 57 and 58 illustrate this situation.
When the third b-sheet is completed at size 3  2nt, the
fibril growth continues by lengthwise attachment of the
next protein monomer (see the fibrils with n ¼ 84 and 85
in Fig. 2). Subsequent lengthwise attachment of monomers
to the fibril is thermodynamically favored only up to size
n ¼ 3  3nt (that of the fibril with n ¼ 126 in Fig. 2),
because between this size and the size n ¼ 4  4nt, to
keep its shape close to the CNT equilibrium shape, the fibril
has to increase its thickness by one more b-sheet. Thus, it
can again be assumed that the fibril of size n ¼ 3  3nt þ 1
(which is the nucleus size in a respective supersaturation
range (52)) will have the shape of a triple b-sheet, i.e.,
a 3b-sheet, of length 3nt with one monomer adsorbed on
the surface of the fibril outer b-sheets (see the fibril with
n ¼ 127 in Fig. 2). Further growth of the fibril can be ex-
pected to occur in the above manner provided it is not
disturbed by other processes, e.g., fibril flocculation.Nanofibril size distribution
As known from nucleation theory (e.g., Kashchiev (57)), the
stationary size distribution of the aggregates of a nucleating
single-component phase can be presented exactly as (n ¼
1,2,3,.)
Xn ¼ Cn
PM1
k¼ n

1
fkCk

PM1
k¼ 1

1
fkCk
; (4)
when nucleation takes place by the Szilard-Farkas mecha-
nism, according to which the aggregates change size by
random attachment and detachment solely of monomeric
building units. Here n (or k) is the number of building units
in an aggregate, Xn (m
3) is the stationary concentration of
n-sized aggregates, Cn (m
3) is the respective equilibrium
concentration of such aggregates, M is the number of
building units in a large enough supernucleus aggregate,
and fn (s
1) is the frequency of building-unit attachment
to an n-sized aggregate.
Equation 4 is readily applicable to nucleation of amyloid
fibrils in the case when the process occurs by the mechanism
of direct polymerization of b-strands into b-sheets. Then n is
the number of b-strands in an n-sized amyloid nanofibril
and, according to ANT, Cn and fn are of the form (52)
Cn ¼ C1 exp½ðn 1Þs ðln  2Þj ðlh;n  2Þjh; (5)
1
fn ¼
2
f1ln; (6)when only the nearest-neighbor interactions between the
b-strands are taken into account.
In Eqs. 5 and 6, C1 (m
3) is the actual concentration of
single b-strands in the protein solution, and f1 (s
1) is the
frequency of attachment of a single b-strand to another
single b-strand. Physically, the sum in the exponent of
Eq. 5, taken with minus sign, is the ratio between the
work Wn to form a fibril of size n and the thermal energy
kBT (kB is the Boltzmann constant, T is the absolute temper-
ature). For sufficiently dilute solutions, the dimensionless
supersaturation s is given by
s ¼ lnC1
Ce
; (7)
where Ce (m
3) is the equilibrium concentration of singleb-strands in the solution (Ce is also known as the protein
solubility). The dimensionless energies j and jh per strong
(mainly hydrogen) and weak (hydrophobicity-mediated)
broken bond are defined by
j ¼ E
2kBT
; (8)
Eh
jh ¼ 2kBT: (9)
Equations 4 and 5 show that both the equilibrium and the
stationary concentrations Cn and Xn of amyloid nanofibrils
of a given size n increase strongly with increasing the solu-
tion supersaturation s, i.e., with a rise of the actual b-strand
concentration C1 and/or a fall of the protein solubility Ce.
As to Eq. 6, in it the proportionality of fn to ln reflects the
fact that the b-strands are attached predominantly to the
ends of the fibril b-sheets (the fibril strong broken bonds
are namely at these ends), and the divisor 2 takes into account
that a single b-strand has l1 ¼ 2 strong broken bonds.
Combining Eqs. 4–9, we find that when only the nearest-
neighbor b-strand interactions are accounted for, the sought
stationary fibril size distribution Xn is given by the general
ANT formula (n ¼ 1,2,3,.) as
Xn ¼ Cn
PM1
k¼ n

1
lk

Ce
C1
k
expðlkjþ lh;kjhÞ
PM1
k¼ 1

1
lk

Ce
C1
k
expðlkjþ lh;kjhÞ
; (10)
in which
Cn ¼ Ce

C1
Ce
n
exp½ð2 lnÞjþ ð2 lh;nÞjh (11)
is the respective equilibrium fibril size distribution.
Equation 10 is a central result of this study. We emphasize
that it is highly reliable, because it is based on the exactBiophysical Journal 101(9) 2232–2241
2236 Cabriolu et al.Eq. 4 and because in it the ratio of the two sums is practi-
cally unaffected by the approximate character of Eq. 6 for
fn. Importantly, Eq. 11 is in conformity with the law of
mass action because of the proportionality of Cn to C1
n.
Also, as a single b-strand has l1 ¼ 2 strong and lh,1 ¼ 2
weak broken bonds, Eq. 11 is self-consistent in the sense
that at n ¼ 1 it returns the identity C1 ¼ C1.
It should be borne in mind that Eq. 10 is applicable solely
to a supersaturated protein solution (i.e., when C1 > Ce),
because the stationary size distribution Xn can exist in
such a solution only. As then the solution is metastable
with respect to fibril nucleation and growth, Xn replaces
the equilibrium size distribution Cn that, albeit mathemati-
cally well defined, has no physical reality because of the
solution metastability. When C1 ¼ Ce or C1 < Ce, however,
the solution is saturated or undersaturated, respectively, and
neither nucleation nor growth are possible, for then the
solution is thermodynamically stable with respect to these
processes. In such a solution, it is the stationary size distri-
bution Xn that is physically irrelevant and the fibril popula-
tion is described by the equilibrium size distributionCn from
Eq. 5 or Eq. 11.TABLE 1 Parameter values related to the size distribution
of nanosized fibrils of wild-type and point-mutated Ab40 at
T ¼ 300 K; the corresponding basic hydrogen-bond energy
is ε ¼ 6.95  1021 J
Ab40 Wild-type V18N V18R V18P
E (J) 1.76  1019 1.72  1019 1.68  1019 1.65  1019
Eh (J) 1.32  1020 1.32  1020 1.32  1020 1.32  1020
j 21.3 20.8 20.3 19.9
jh 1.59 1.59 1.59 1.59
nt 14 14 13 13
Ce (mM) 3.9 10.6 28.8 64.1Changes in fibril solubility due to point mutations
The integrated van’ t Hoff equation
Ce ¼ Cr exp

 L
kBT

; (12)
in which Cr (m
3) is a reference protein concentration,
relates the equilibrium concentration Ce to the latent heat
or enthalpy L (J) (per b-strand) of protein aggregation
(e.g., Kashchiev and Auer (51) and Auer and Kashchiev
(58)). As found elsewhere (58), in line with the Haas-Drenth
lattice model of protein crystals (59), L is approximately
given by half of the average binding energy hEbi of a
b-strand within the bulk fibrillar phase, i.e., L z hEbi/2.
For the fibril model considered here, we have hEbi ¼
2(Eþ Eh)¼ 4(jþ jh)kBT, where E, Eh, j, and jh are given
by Eqs. 1, 2, 8, and 9. Hence, approximately,
L ¼ Eþ Eh ¼ 2ðjþ jhÞkBT: (13)
If sW and sM are the supersaturations for a wild-type and
a point-mutated protein, respectively, employing Eqs. 7
and 12, we find that the change Dsh sM  sW in the super-
saturation upon a point mutation of the wild-type protein at
the same temperature T and monomer concentration C1 is of
the form
Ds ¼ LM  LW
kBT
: (14)
The latent heat LW or LM (per b-strand) of the wild-type
protein or the mutant can be calculated from Eq. 13 whenBiophysical Journal 101(9) 2232–2241the corresponding binding energies E and Eh are known.
Also, if Ce,W and Ce,M are the solubilities of the wild-type
and the point-mutated protein, respectively, the mutation-
affected change in the protein solubility at the same temper-
ature can be characterized by the ratio
Ce;M
Ce;W
¼ exp

LW  LM
kBT

: (15)
This formula follows from Eq. 12 provided the point muta-
tion has practically no effect on Cr.RESULTS AND DISCUSSION
Application to Ab40 nanofibrils
Our considerations pertain to that molecular structure
proposed by Sachse et al. (60) for Ab40 fibrils, in which
the b-strand is formed by a long amino-acid stretch at the
C-terminal tail of the protein monomer. As in our previous
study (54), we rely on theoretical models (44,45) that
identify the most aggregation-prone amino acids in proteins.
The theoretical algorithm by Trovato et al. (45) predicts
that amino acids 12–20 (VHHQKLVFF) and 31–40
(IIGLMVGGVV) are the most aggregation-prone ones
(V ¼ Valine, H ¼ Histidine, Q ¼ Glutamine, K ¼ Lysine,
L ¼ Leucine, F ¼ Phenylalanine, I ¼ Isoleucine, G ¼
Glycine, M ¼ Methionine). Joint together, these 19 amino
acids form a sequence that defines the b-strand in our nano-
fibril model (Fig. 1). The sequence-specific energy εjq of the
hydrogen bond between amino acids j and q can vary in the
interval [0, 2ε], depending on the frequency with which two
residue types are found paired in neighboring b-strands
within a b-sheet in globular proteins (see Eq. 3). For
simplicity, we assume that the energy εh,jq of a hydropho-
bicity-mediated bond is the same for all amino-acid pairs,
so that εh,jq ¼ εh, and we set εh ¼ ε/10.
With this set of parameter values, the interstrand binding
energies E and Eh for the b-strands (VHHQKLVFFIIGL
MVGGVV) arranged parallel within wild-type Ab40 fibrils
can be calculated from Eqs. 1–3, and are E ¼ 25.4ε and
Eh ¼ 1.9ε (see also Table 1). Accordingly, the rounded-up
ratio between the b-strand strong and weak binding energies
Size Distribution of Amyloid Nanofibrils 2237is E/Eh ¼ 14, and the fibril transition size is thus nt ¼ 14
(Table 1) because of our assumption that it is given by the
CNT formula (51) nt ¼ E/Eh, which characterizes the fibril
equilibrium shape. We note, however, that during nucleation
the fibrils are under nonequilibrium conditions: on average,
they grow and thus assume a kinetically determined growth
shape that may differ considerably from the equilibrium
one. Computer simulation data (see Fig. 2 in Zhang and
Muthukumar (30)) indicate that the fibril kinetic aspect
(length/thickness) ratio that quantifies the fibril growth
shape can be several times greater than the thermodynamic
aspect ratio E/Eh, i.e., that the fibrils can grow longer than it
is thermodynamically expected. It should be kept in mind
therefore that, actually, the fibril transition size nt may
have values considerably greater than the value of E/Eh
assumed in our analysis.Ab40 nanofibril size distribution: supersaturation
dependence
The nanofibril size distribution for wild-type Ab40 solution
at T ¼ 300 K and supersaturations s/jh ¼ 0.9, 1, 1.2, 2, and
2.5 are displayed in Fig. 3 by lines 0.9, 1, 1.2, 2, and 2.5,
respectively. The lines are obtained from Eq. 10 by setting
M ¼ 300 (as in Cabriolu et al. (52)) and by using the ln
and lh,n values from Table S1 in the Supporting Material
and the j- and jh-values following from Eqs. 8 and 9 and
given in Table 1. According to Eq. 7, with jh from Table
1, the above supersaturations correspond to supersaturation
ratios C1/Ce ¼ 4.20, 4.90, 6.78, 24.0, and 53.3, respectively.FIGURE 3 Stationary nanofibril size distribution Xn on (a) Xn
1/5 and (b)
log Xn scale according to Eq. 10 at T ¼ 300 K and supersaturations s/jh ¼
0.9, 1, 1.2, 2, and 2.5 (as indicated) for wild-type Ab40.As seen in Fig. 3, Eq. 10 predicts a series of peaks, each of
them being at a certain fixed fibril size for high enough
supersaturations and at a smaller, but again fixed, size for
sufficiently low supersaturations. The first peak is posi-
tioned either at fibril size n01 or at fibril size n001 > n01
that, due to our choice of the nanofibril evolution mecha-
nism illustrated in Fig. 2, are given by n01 ¼ 1 (for 0 <
s < 2jh) and by n
00
1 ¼ nt (for s > 2jh), where nt ¼ 14
and 2jh ¼ 3.18 because of the j- and jh-values used in
our calculation of Xn in Fig. 3. At s ¼ 2jh (line 2), the
peak is plateaulike, extending from n ¼ n01 to n ¼ n001,
i.e., from the monomer size to the fibril size nt for transition
of the fibril from one-dimensional to two-dimensional
aggregate.
Similarly, the fibril sizes n0j and n00j at which the second,
third, etc. peaks are positioned at low or high supersatura-
tions, respectively, are obtainable from the relations (j ¼
2,3,4,.),
n0j ¼ jð j  1Þnt (16)
(for 0 < s < 2jh/j) and
n00j ¼ j2nt (17)
(for s> 2jh/j). At s¼ 2jh/j, the jth peak is a plateau (jagged
for j ¼ 2,3,4,.) that extends from n ¼ n0j to n ¼ n00j. In
Fig. 2, the first three nanofibrils of size n0j and of size n00j
are colored pink and blue, respectively.
Fig. 2 and Eqs. 16 and 17 show that both the n0j-sized and
the n00j-sized fibrils are constituted of j b-sheets, but their
lengths m0j and m00j, respectively, are multiples of nt (except
m01 ¼ 1):
m0j ¼ ð j  1Þnt; (18)
m00 ¼ jnt: (19)j
Equations 16 and 17 show also that for s> 2jh, i.e., for high
enough supersaturations, all peaks (including the first one)
remain fixed at characteristic or ‘‘magic’’ fibril sizes n00j
given by Eq. 17. The n00j-sized fibril itself is j b-sheets thick
and jnt b-strands long (see the blue fibrils in Fig. 2), i.e., its
length m00j is determined by Eq. 19. This equation implies
that when s > 2jh, if plotted as a function of the nanofibril
length m, the stationary size distribution of the nanofibrils
will be multipeaked at magic lengths m00j, the peaks being
at the same distance nt from their nearest neighbors on the
m axis. We note, however, that this result about equidis-
tanced peaks in the nanofibril length distribution character-
izes the nanofibril shape sequence illustrated in Fig. 2.
Deviations from this sequence, in particular regarding the
length at which the nanofibril acquires the energetically
very costly b-strand that gives birth of its subsequentBiophysical Journal 101(9) 2232–2241
2238 Cabriolu et al.b-sheet, could lead to different interpeak distances on the
nanofibril length axis.
Combining Eq. 17 with the formula n*j ¼ j2nt þ 1 for the
successive nucleus sizes n*j (52), we arrive at the equation
(j ¼ 1,2,3,4,.)
nj ¼ n00j þ 1; (20)
which says that the jth fibril nucleus is just one b-strand
bigger than the fibril corresponding to the jth peak at high
enough supersaturations (see Fig. 2 in which the first three
fibril nuclei are hatched, and the n00j-sized fibrils are blue).
Equation 20 is of particular interest, for it seems to be
a result of general validity when amyloid fibrils are nucle-
ated by the mechanism of direct polymerization of b-strands
and when s > 2jh. According to this equation, with a negli-
gible difference of one b-strand, the positions n00j of the
peaks in a nanofibril size distribution that is obtained in
a real or computer experiment at a high enough supersatura-
tion s merely represent the sizes n*j of the successive fibril
nuclei.
Table S2 lists the first three values of n0j, m0j, n00j, and m00j
in the respective s ranges. To get a feel of these values for the
Ab40 protein, we recall that the molecular mass of the
protein monomer is 4.3 kDa (61), and that the distance
between b-strands in the Ab40 fibril is ~0.47 nm (62).
Hence, from Eqs. 17 and 19 with nt ¼ 14, the first three
peaks of the nanofibril mass or length distribution are at
magic masses 4.3 n00j of 60.2, 241, and 542 kDa or lengths
0.47 m00j of 6.58, 13.2, and 19.7 nm provided the solution
is at supersaturation s > 2jh ¼ 3.18.
The physical reason for which the size distribution Xn of
nanosized fibrils is peaked at magic sizes n0j or n00j is the
presence of deep local minima of theworkWn to form a fibril
of n b-strands (see Fig. 3b of Cabriolu et al. (52)). The
attachment of a b-strand to the end of an n0j-sized fibril or
to the surface of an n00j-sized fibril requires considerable
work so that the n0j- or n00j-sized fibrils become the most
numerous in the solution and thus give rise to peaks in the
nanofibril size distribution. As to the s value at which the
jth peak is plateaulike, it coincides with that at which,
according to CNT (Kashchiev and Auer (51), Eq. 13), a
jb-sheet is in thermodynamic equilibrium with the solution,
i.e., it neither grows nor dissolves. We note as well that,
regardless of the s value, a given peak concentration Xp, j
is always higher than the subsequent concentration Xp, jþ1,
i.e., the peak concentrations of the nanofibrils obey the order
Xp,1R Xp,2 R Xp,3 R. .
Clearly, Xn will be closer to a monotonically decreasing
function of n when the work (s þ 2j)kBT (Kashchiev
and Auer (51)) of thicknesswise b-strand attachment to
the kinkless surface of any of the n00j-sized fibrils (Fig. 2)
is sufficiently smaller than the thermal energy kBT. Thus,
the condition for relatively low peaks in the stationary nano-
fibril size distribution readsBiophysical Journal 101(9) 2232–22412j<1þ s: (21)
This condition shows that, as usually j > 1, well-pro-
nounced peaks at magic sizes (or lengths) are to be expected
in the stationary size (or length) distributions of most
amyloid nanofibrils (the effect of the supersaturation is quite
small, because amyloid fibril nucleation occurs at s values
considerably smaller than those of j (51,52)). For nanofi-
brils of shorter b-strands the peaks will be less pronounced,
because j diminishes with decreasing b-strand length. In
principle, any biophysicochemical factor that lessens the
j-value will also contribute to the suppression of the Xn
peaks and, hence, to the possible disappearance of the magic
nanofibril sizes or lengths.
Preferred sizes, lengths, or thicknesses of Ab oligomers
or fibrils have been recorded in many experiments (e.g.,
(29,61–65)). In this respect, our finding of magic sizes is
in qualitative agreement with experiment. No experimental
data we are aware of, however, allows us using it for a quan-
titative verification of this finding. Reported histograms of
the fibril mass-per-length ratio (60,61,63–69) exhibit one
or more peaks, but pertain to portions of rather long fibrils
and show that these usually contain an integer number of
b-sheets. To reliably quantify the magic nanofibril sizes,
we need histograms of the masses of entire fibrils with nano-
scale lengths. To the best of our knowledge, only Goldsbury
et al. (61) have obtained such a histogram (Fig. 4D in their
article), but it is for pseudospherical rather than fibrillar
Ab40 aggregates and the authors could fit it by two Gaussian
curves with maxima at masses of 311 and 554 kDa corre-
sponding to 72 and 128 protein molecules. The experi-
mental size distributions of Garai et al. (29) for solutions
of Ab40 also exhibit peaks at magic sizes represented by
the aggregate hydrodynamic radii. Again, a quantitative
comparison between our theory and the experiment of Garai
et al. (29) is not possible. The reported size distributions are
not stationary, the aggregate morphology is unknown, and
the second peak of the size distributions is at radius of
~50 nm. This radius corresponds to the rather large number
of 1.2  105 protein molecules if, as in Garai et al. (29), one
uses 4.3 nm3 for the Ab40 molecular volume and assumes
that the aggregates are spherical.
Very interesting are as well the experimental data of
Kellermayer et al. (62), which support our finding of
magic nanofibril lengths. These authors have presented a
histogram of most frequently observed increments of the
lengths of epitaxially growing individual Ab25-35 fibrils
(the inset in Fig. 2a of Kellermayer et al. (62)). The histo-
gram exhibits five successive peaks at 6.5, 13.3, 23.2,
32.5, and 40 nm. As noted by Kellermayer et al. (62), the
nearly 7-nm interpeak distance ‘‘corresponds to a stretch
of fibril containing z15 peptides along its length.’’ This is
in close quantitative agreement with our finding for peaks
in the Ab40 nanofibril length distribution, which are equidis-
tanced at 14 b-strands or, equivalently, 6.6 nm. However,
FIGURE 4 Stationary nanofibril size distribution on (a) Xn
1/5 and (b) log
Xn scale according to Eq. 10 at T¼ 300 K and monomer concentration C1¼
120 mM for wild-type Ab40 and its mutants V18N, V18R, and V18P:
(black) line WT, wild-type; (red) line N, V18N; (green) line R, V18R;
and (blue) line P, V18P.
Size Distribution of Amyloid Nanofibrils 2239this agreement is very likely to be fortuitous, because
whereas the fibrils of Kellermayer et al. (62) elongate at
a practically constant thickness, according to our model
(Fig. 2) every subsequent fibril lengthening of nt b-strands
is preceded by fibril thickening of one b-sheet.Ab40 nanofibril size distribution: effect of
mutations
The presented theoretical framework enables us also to
study the effect of point mutations on the nanofibril size
distribution. In particular, at fixed T and C1, we examine
how Xn is affected by the point mutations of residue 18
(V) with amino acids Asparagine (N), Arginine (R), and
Proline (P), because the effect of these mutations of Ab40
on the fibrillation kinetics has been investigated experimen-
tally (35).
To be able to calculate Xn from Eq. 10 for each mutant, we
need to know the corresponding fibril solubility Ce and
energy parameters j and jh that have different values for
each mutant, because the binding energies E and Eh of the
b-strands within the fibrils are different (see Table 1). For
the wild-type Ab40, we employ the experimentally obtained
Ce ¼ 3.9 mM at T ¼ 300 K (29). As Ce has not been deter-
mined experimentally for any of the mutants, we find it
theoretically by making use of Eqs. 13 and 15 and the
j- and jh-values from Table 1. The Ce values computed
in this way for fibrils with point mutations V18N, V18R,
and V18P are given in Table 1. Using the procedure outlinedabove for the wild-type Ab40, from Eq. 10 we calculate Xn
for each mutant by setting M ¼ 300 (as in Cabriolu et al.
(52)) and by using the j- and jh-values from Table 1 and
the ln and lh,n values from Table S1 and Table S3. For muta-
tions V18N, V18R, and V18P the transition size nt ¼ E/Eh
has the values 14, 13, and 13, respectively, and is equal or
nearly equal to the transition size nt ¼ 14 for the wild-
type protein (Table 1).
The nanofibril size distributions obtained at T ¼ 300 K
and C1 ¼ 120 mM are shown in Fig. 4. At this concentration,
the supersaturation for the wild-type protein and the three
mutants V18N, V18R, and V18P can be calculated from
Eq. 7 and is s ¼ 3.43, 2.43, 1.43, and 0.63, respectively.
As can be seen in Fig. 4, the main effect of the mutations
is that the peaks for all magic nanofibril sizes n0j or n00j
lose height. This is so because by considerably increasing
the fibril solubility, the mutations lower the solution super-
saturation, which leads to a strong decrease in the entire
fibril population and, accordingly, in the peak heights. In
contrast, the effect of the mutations on n0j or n00j is minor
(because nt changes only from 14 to 13 for two of the
mutants) and, as a result, the peak positions remain essen-
tially the same. For mutant V18R, the second peak is at
n02 ¼ 26, because the Ce value for this mutant is so great
that the corresponding supersaturation ratio C1/Ce is too
low for the peak to be at n002 ¼ 52.
The effect of mutations on the fibril population could be
exemplified by considering the number of nanofibrils of 13
b-strands in a solution of volume V¼ 100 mL typically used
in experiments. From Eq. 10 (see also Fig. 4) we calculate
that whereas the number X13V of wild-type fibrils of size
n ¼ 13 is 1020, the V18N and V18R fibrils of the same
size are much less numerous: the V18N ones are 9  1014,
and the V18R ones are 1010. Remarkably, the fibrils of
the same size for mutant V18P are practically absent from
the solution, because their number is 4  105. It is worth
noting also that the decrease of the peak heights for the
different mutants that is seen in Fig. 4 is consistent with
experiments on protein fibrillation kinetics (35), which
reveal that the lag time before detectable fibrillation is
longer for the mutants V18N and V18R than for the wild-
type Ab40; and that the mutant V19P is not detectable at
all. This consistency is in support of the correlation reported
earlier (54) between ANT nucleation rates of amyloid
fibrils and experimentally measured fibrillation lag-times
of wild-type and point-mutated Ab proteins.CONCLUSION
The analysis made illustrates the ability of the nucleation
theory to describe the size distribution of amyloid nanofi-
brils in protein solutions when nucleation occurs by the
mechanism of direct polymerization of b-strands into
b-sheets. The atomistic modeling of the nanofibrils of
successively layered b-sheets leads to a general formulaBiophysical Journal 101(9) 2232–2241
2240 Cabriolu et al.(Eq. 10) for the stationary size distribution as a function of
the protein concentration and of the temperature (via Ce, j,
and jh that, given the nanofibril shape sequence, are the
only three theoretical parameters). Application of this
formula to Ab40 nanofibrils reveals the existence of a series
of characteristic peaks in the size distribution, which are
positioned at magic nanofibril sizes (or lengths) and which
are due to the sufficiently deep local minima in the work
for fibril formation. This finding of magic sizes or lengths
is consistent with experimental results for the size distribu-
tion of aggregates in solutions of Ab40 proteins.
We believe our analysis provides a new opportunity to
obtain information about the sizes of the successive fibril
nuclei, because according to Eq. 20, these sizes are practi-
cally equal to the magic sizes at which the nanofibril size
distribution is peaked when the solution supersaturation is
sufficiently high. Also, we believe our atomistic approach
makes it possible to gain novel insight into the effect of
point mutations on the size distribution of amyloid nanofi-
brils, an effect that may play a role in experimentally
observed substantial differences in the fibrillation lag-times
of wild-type and point-mutated Ab proteins.
The results obtained remain without quantitative verifica-
tion because of the lack of suitable experimental or simula-
tion data for the size distribution of amyloid nanofibrils. It is
hoped that our study will inspire new real and computer
experiments especially aimed at investigating this distribu-
tion and/or the magic nanofibril sizes or lengths.SUPPORTING MATERIAL
Three tables are available at http://www.biophysj.org/biophysj/
supplemental/S0006-3495(11)01184-2.
This work was supported by Engineering and Physical Science Research
Council grant No. EP/G026165/1.REFERENCES
1. Chiti, F., and C. M. Dobson. 2006. Protein misfolding, functional
amyloid, and human disease. Annu. Rev. Biochem. 75:333–366.
2. Gazit, E. 2007. Self-assembled peptide nanostructures: the design of
molecular building blocks and their technological utilization. Chem.
Soc. Rev. 36:1263–1269.
3. Sunde, M., and C. Blake. 1997. The structure of amyloid fibrils by elec-
tron microscopy and x-ray diffraction. Adv. Protein Chem. 50:123–159.
4. Jaroniec, C. P., C. E. MacPhee,., R. G. Griffin. 2004. High-resolution
molecular structure of a peptide in an amyloid fibril determined by
magic angle spinning NMR spectroscopy. Proc. Natl. Acad. Sci.
USA. 101:711–716.
5. Makin, O. S., E. Atkins, ., L. C. Serpell. 2005. Molecular basis for
amyloid fibril formation and stability. Proc. Natl. Acad. Sci. USA.
102:315–320.
6. Tycko, R. 2006. Molecular structure of amyloid fibrils: insights from
solid-state NMR. Q. Rev. Biophys. 39:1–55.
7. Sawaya, M. R., S. Sambashivan,., D. Eisenberg. 2007. Atomic struc-
tures of amyloid cross-b spines reveal varied steric zippers. Nature.
447:453–457.Biophysical Journal 101(9) 2232–22418. Wasmer, C., A. Lange, ., B. H. Meier. 2008. Amyloid fibrils of the
HET-s(218-289) prion form a b-solenoid with a triangular hydrophobic
core. Science. 319:1523–1526.
9. Serio, T. R., A. G. Cashikar, ., S. L. Lindquist. 2000. Nucleated
conformational conversion and the replication of conformational infor-
mation by a prion determinant. Science. 289:1317–1321.
10. Auer, S., C. M. Dobson, andM. Vendruscolo. 2007. Characterization of
the nucleation barriers for protein aggregation and amyloid formation.
HFSP J. 1:137–146.
11. Auer, S., F. Meersman, ., M. Vendruscolo. 2008. A generic mecha-
nism of emergence of amyloid protofilaments from disordered oligo-
meric aggregates. PLOS Comput. Biol. 4:e1000222.
12. Hofrichter, J., P. D. Ross, and W. A. Eaton. 1974. Kinetics and mech-
anism of deoxyhemoglobin S gelation: a new approach to under-
standing sickle cell disease. Proc. Natl. Acad. Sci. USA. 71:4864–4868.
13. Ferrone, F. A., J. Hofrichter, and W. A. Eaton. 1985. Kinetics of sickle
hemoglobin polymerization. I. Studies using temperature-jump and
laser photolysis techniques. J. Mol. Biol. 183:591–610.
14. Ferrone, F. A., J. Hofrichter, and W. A. Eaton. 1985. Kinetics of sickle
hemoglobin polymerization. II. A double nucleation mechanism.
J. Mol. Biol. 183:611–631.
15. Hofrichter, J. 1986. Kinetics of sickle hemoglobin polymerization. III.
Nucleation rates determined from stochastic fluctuations in polymeri-
zation progress curves. J. Mol. Biol. 189:553–571.
16. Jarrett, J. T., and P. T. Lansbury, Jr. 1993. Seeding ‘‘one-dimensional
crystallization’’ of amyloid: a pathogenic mechanism in Alzheimer’s
disease and scrapie? Cell. 73:1055–1058.
17. Lomakin, A., D. S. Chung,., D. B. Teplow. 1996. On the nucleation
and growth of amyloid b-protein fibrils: detection of nuclei and quan-
titation of rate constants. Proc. Natl. Acad. Sci. USA. 93:1125–1129.
18. Lomakin, A., D. B. Teplow,., G. B. Benedek. 1997. Kinetic theory of
fibrillogenesis of amyloid b-protein. Proc. Natl. Acad. Sci. USA.
94:7942–7947.
19. Harper, J. D., and P. T. Lansbury, Jr. 1997. Models of amyloid seeding
in Alzheimer’s disease and scrapie: mechanistic truths and physiolog-
ical consequences of the time-dependent solubility of amyloid proteins.
Annu. Rev. Biochem. 66:385–407.
20. Galkin, O., and P. G. Vekilov. 2004. Mechanisms of homogeneous
nucleation of polymers of sickle cell anemia hemoglobin in deoxy
state. J. Mol. Biol. 336:43–59.
21. Nguyen, H. D., and C. K. Hall. 2004. Molecular dynamics simulations
of spontaneous fibril formation by random-coil peptides. Proc. Natl.
Acad. Sci. USA. 101:16180–16185.
22. Nguyen, H. D., and C. K. Hall. 2005. Kinetics of fibril formation by
polyalanine peptides. J. Biol. Chem. 280:9074–9082.
23. Nguyen, H. D., and C. K. Hall. 2006. Spontaneous fibril formation by
polyalanines; discontinuous molecular dynamics simulations. J. Am.
Chem. Soc. 128:1890–1901.
24. Ferrone, F. A. 2006. Nucleation: the connections between equilibrium
and kinetic behavior. Methods Enzymol. 412:285–299.
25. Galkin, O., R. L. Nagel, and P. G. Vekilov. 2007. The kinetics of
nucleation and growth of sickle cell hemoglobin fibers. J. Mol. Biol.
365:425–439.
26. Linse, S., C. Cabaleiro-Lago, ., K. A. Dawson. 2007. Nucleation of
protein fibrillation by nanoparticles. Proc. Natl. Acad. Sci. USA.
104:8691–8696.
27. Auer, S., C. M. Dobson, ., A. Maritan. 2008. Self-templated nucle-
ation in peptide and protein aggregation. Phys. Rev. Lett. 101:258101.
28. Xue, W. F., S. W. Homans, and S. E. Radford. 2008. Systematic anal-
ysis of nucleation-dependent polymerization reveals new insights into
the mechanism of amyloid self-assembly. Proc. Natl. Acad. Sci. USA.
105:8926–8931.
29. Garai, K., B. Sahoo,., S. Maiti. 2008. Quasihomogeneous nucleation
of amyloid b yields numerical bounds for the critical radius, the surface
tension, and the free energy barrier for nucleus formation. J. Chem.
Phys. 128:045102.
Size Distribution of Amyloid Nanofibrils 224130. Zhang, J., and M. Muthukumar. 2009. Simulations of nucleation and
elongation of amyloid fibrils. J. Chem. Phys. 130:035102.
31. Nielsen, L., R. Khurana,., A. L. Fink. 2001. Effect of environmental
factors on the kinetics of insulin fibril formation: elucidation of the
molecular mechanism. Biochemistry. 40:6036–6046.
32. Kim, Y. S., S. P. Cape,., J. F. Carpenter. 2001. Counteracting effects
of renal solutes on amyloid fibril formation by immunoglobulin light
chains. J. Biol. Chem. 276:1626–1633.
33. Zhu, L., X. J. Zhang, ., S. Perrett. 2003. Relationship between
stability of folding intermediates and amyloid formation for the yeast
prion Ure2p: a quantitative analysis of the effects of pH and buffer
system. J. Mol. Biol. 328:235–254.
34. Kunes, K. C., D. L. Cox, and R. R. P. Singh. 2005. One-dimensional
model of yeast prion aggregation. Phys. Rev. E. 72:051915.
35. Christopeit, T., P. Hortschansky, ., M. Fa¨ndrich. 2005. Mutagenic
analysis of the nucleation propensity of oxidized Alzheimer’s
b-amyloid peptide. Protein Sci. 14:2125–2131.
36. Hortschansky, P., V. Schroeckh, ., M. Fa¨ndrich. 2005. The aggrega-
tion kinetics of Alzheimer’s b-amyloid peptide is controlled by
stochastic nucleation. Protein Sci. 14:1753–1759.
37. Pedersen, J. S., J. M. Flink,., D. E. Otzen. 2006. Sulfates dramatically
stabilize a salt-dependent type of glucagon fibrils. Biophys. J. 90:4181–
4194.
38. Grudzielanek, S., V. Smirnovas, and R. Winter. 2006. Solvation-
assisted pressure tuning of insulin fibrillation: from novel aggregation
pathways to biotechnological applications. J. Mol. Biol. 356:497–509.
39. Fa¨ndrich, M. 2007. Absolute correlation between lag time and growth
rate in the spontaneous formation of several amyloid-like aggregates
and fibrils. J. Mol. Biol. 365:1266–1270.
40. Routledge, K. E., G. G. Tartaglia,., S. E. Radford. 2009. Competition
between intramolecular and intermolecular interactions in an amyloid-
forming protein. J. Mol. Biol. 389:776–786.
41. Hellstrand, E., B. Boland, ., S. Linse. 2009. Amyloid Iˆ2-protein
aggregation produces highly reproducible kinetic data and occurs by
a two-phase process. Am. Chem. Soc. Chem. Neurosci. 1:13–18.
42. Chiti, F., M. Stefani, ., C. M. Dobson. 2003. Rationalization of the
effects of mutations on peptide and protein aggregation rates. Nature.
424:805–808.
43. Yoon, S., and W. J. Welsh. 2004. Detecting hidden sequence propensity
for amyloid fibril formation. Protein Sci. 13:2149–2160.
44. Fernandez-Escamilla, A. M., F. Rousseau,., L. Serrano. 2004. Predic-
tion of sequence-dependent and mutational effects on the aggregation
of peptides and proteins. Nat. Biotechnol. 22:1302–1306.
45. Trovato, A., F. Chiti, ., F. Seno. 2006. Insight into the structure of
amyloid fibrils from the analysis of globular proteins. PLOS Comput.
Biol. 2:e170.
46. Tartaglia, G. G., A. P. Pawar,., M. Vendruscolo. 2008. Prediction of
aggregation-prone regions in structured proteins. J. Mol. Biol.
380:425–436.
47. Vestergaard, B., M. Groenning,., D. I. Svergun. 2007. A helical struc-
tural nucleus is the primary elongating unit of insulin amyloid fibrils.
PLoS Biol. 5:e134.
48. Oliveira, C. L., M. A. Behrens,., J. S. Pedersen. 2009. A SAXS study
of glucagon fibrillation. J. Mol. Biol. 387:147–161.
49. Garai, K., R. Sureka, and S. Maiti. 2007. Detecting amyloid-b aggrega-
tion with fiber-based fluorescence correlation spectroscopy. Biophys. J.
92:L55–L57.50. Auer, S., and D. Kashchiev. 2010. Insight into the correlation between
lag time and aggregation rate in the kinetics of protein aggregation.
Proteins Struct. Funct. Bioinform. 78:2412–2416.
51. Kashchiev, D., and S. Auer. 2010. Nucleation of amyloid fibrils.
J. Chem. Phys. 132:215101.
52. Cabriolu, R., D. Kashchiev, and S. Auer. 2010. Atomistic theory of
amyloid fibril nucleation. J. Chem. Phys. 133:225101.
53. Schmit, J. D., K. Ghosh, and K. Dill. 2011. What drives amyloid mole-
cules to assemble into oligomers and fibrils? Biophys. J. 100:450–458.
54. Cabriolu, R., and S. Auer. 2011. Amyloid fibrillation kinetics: insight
from atomistic nucleation theory. J. Mol. Biol. 411:275–285.
55. Kashchiev, D. 2008. Toward a better description of the nucleation rate
of crystals and crystalline monolayers. J. Chem. Phys. 129:164701.
56. Fersht, A. R., J.-P. Shi, ., G. Winter. 1985. Hydrogen bonding and
biological specificity analyzed by protein engineering. Nature.
314:235–238.
57. Kashchiev, D. 2000. Nucleation: Basic Theory with Applications.
Butterworth Heinemann, Oxford, UK.
58. Auer, S., and D. Kashchiev. 2010. Phase diagram of a-helical and
b-sheet forming peptides. Phys. Rev. Lett. 104:168105.
59. Haas, C., and J. Drenth. 1995. The interaction energy between two
protein molecules related to physical properties of their solution and
their crystals and implications for crystal growth. J. Cryst. Growth.
154:126–135.
60. Sachse, C., M. Fa¨ndrich, and N. Grigorieff. 2008. Paired b-sheet struc-
ture of an Ab (1-40) amyloid fibril revealed by electron microscopy.
Proc. Natl. Acad. Sci. USA. 105:7462–7466.
61. Goldsbury, C. S., S. Wirtz, ., P. Frey. 2000. Studies on the in vitro
assembly of a b 1-40: implications for the search for a b-fibril forma-
tion inhibitors. J. Struct. Biol. 130:217–231.
62. Kellermayer, M. S., A. Karsai,., B. Penke. 2008. Stepwise dynamics
of epitaxially growing single amyloid fibrils. Proc. Natl. Acad. Sci.
USA. 105:141–144.
63. Antzutkin, O. N., R. D. Leapman,., R. Tycko. 2002. Supramolecular
structural constraints on Alzheimer’s b-amyloid fibrils from electron
microscopy and solid-state nuclear magnetic resonance. Biochemistry.
41:15436–15450.
64. Goldsbury, C., P. Frey, ., S. A. Mu¨ller. 2005. Multiple assembly
pathways underlie amyloid-b fibril polymorphisms. J. Mol. Biol.
352:282–298.
65. Petkova, A. T., Y. Ishii, ., R. Tycko. 2002. A structural model for
Alzheimer’s b-amyloid fibrils based on experimental constraints from
solid state NMR. Proc. Natl. Acad. Sci. USA. 99:16742–16747.
66. Schmidt, M., C. Sachse, ., N. Grigorieff. 2009. Comparison of
Alzheimer Ab (1-40) and Ab (1-42) amyloid fibrils reveals similar pro-
tofilament structures. Proc. Natl. Acad. Sci. USA. 106:19813–19818.
67. Chen, B., K. R. Thurber,., R. Tycko. 2009. Measurement of amyloid
fibril mass-per-length by tilted-beam transmission electron micros-
copy. Proc. Natl. Acad. Sci. USA. 106:14339–14344.
68. Komatsu, H., E. Feingold-Link,., P. H. Axelsen. 2010. Intrinsic linear
heterogeneity of amyloid b protein fibrils revealed by higher resolution
mass-per-length determinations. J. Biol. Chem. 285:41843–41851.
69. Goldsbury, C., U. Baxa,., S. A. Mu¨ller. 2011. Amyloid structure and
assembly: insights from scanning transmission electron microscopy.
J. Struct. Biol. 173:1–13.Biophysical Journal 101(9) 2232–2241
